Jonas Bønnelykke

Jonas Bønnelykke

Auto-generated profile, based on publicly available information

Jonas Bønnelykke

Department of Chemistry, Aarhus University, Langelandsgade 140, Aarhus, 8000, Denmark

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MSMads K. Skaanning
Mads K. Skaanning
JBJonas Bønnelykke
Jonas Bønnelykke
MNMinke A. D. Nijenhuis
Minke A. D. Nijenhuis
ASAnirban Samanta
Anirban Samanta
JSJakob Melgaard Smidt
Jakob Melgaard Smidt
KGKurt Gothelf
Kurt Gothelf

6 February 2023 in Nature Synthesis
Verified
Journal Article
Closed access
PDF file
HHHans Christian D. Hammershøj
Hans Christian D. Hammershøj
HGHaraldur G. Gudmundsson
Haraldur G. Gudmundsson
SKSamuel Kjærsgaard
Samuel Kjærsgaard
JBJonas Bønnelykke
Jonas Bønnelykke
JKJulia Kolodiazhnaia
Julia Kolodiazhnaia
TSTroels Skrydstrup
Troels Skrydstrup

18 February 2025 in Physics in Medicine & Biology
Verified
Journal Article
Open access
VJVillads Jacobsen
Villads Jacobsen
VPVladimir A Pan
Vladimir A Pan
LTLinh Tran
Linh Tran
JVJames Vohradsky
James Vohradsky
JBJonas Bønnelykke
Jonas Bønnelykke
NBNiels Bassler
Niels Bassler
Objective. The clinical advantage of proton therapy, compared to other types of irradiations, lies in its reduced dose to normal tissue. Still, proton therapy faces challenges of normal tissue toxicity and radioresistant tumors. To combat these challenges, proton boron capture therapy (PBCT) and neutron capture enhanced particle therapy (NCEPT) were proposed to introduce high-LET radiation in the target volume. Approach. In this work, we performed in-vitro experiments with a V79 cell line to validate PBCT and introduced a novel approach to use NCEPT in proton therapy. We quantified the effectiveness of PBCT and NCEPT with microdosimetric measurements, Monte-Carlo simulations and microdosimetric kinetic RBE model (MKM). Main results. No RBE increase was observed for PBCT. With the use of a tungsten spallation source, enough neutrons were generated in the incoming proton beam to measure significant neutron capture in the microdosimeter. However, no significant increase of RBE was detected when conventional in vitro protocol was followed. The resulting cell deactivation based RBE for NCEPT was found to be heavily dependent on which criteria was used to determine surviving colonies. Significance. PBCT and NCEPT are two proposed treatment modalities that may have the potential to expand the cases in which proton therapy can be beneficial. Understanding the scope of these treatment methods and developing measurement protocols to evaluate and understand their RBE impact are the first step to quantify their potential in clinical context.